T4 Artificial Virus Assembly for Safe Multipayload Genome Remodeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies face challenges in formulating artificial viruses that can efficiently and safely deliver therapeutic genes and proteins into human cells for genome remodeling, with limitations such as safety concerns, broad infectivity, and difficulty in incorporating multiple therapeutic molecules.
Innovation Solution
A novel artificial virus platform based on bacteriophage T4 is developed, which includes a T4 capsid, Cas9 protein, RNA, DNA, and a lipid coating, allowing for the sequential assembly of therapeutic molecules inside and outside the capsid shell, mimicking natural viruses for efficient cellular entry and genome remodeling operations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional viral vectors are used for gene delivery, then transduction efficiency is achieved, but safety concerns and broad infectivity arise
Solution Approach 1:
The patent creates artificial viruses that copy the structural features of natural viruses (capsid, lipid envelope) without using actual viral genetic material. The T4 bacteriophage capsid is emptied of its natural DNA and repurposed to deliver therapeutic payloads, mimicking viral entry mechanisms while eliminating viral replication risks. This copying approach maintains high transduction efficiency through familiar viral structures while removing harmful viral properties.
Solution Approach 2:
The patent introduces an intermediary system that bridges the gap between bacterial phage structures and human cell delivery. The T4 capsid serves as an intermediary vehicle that has been engineered to recognize and enter human cells through modified surface proteins, while the lipid coating acts as an intermediary layer that facilitates membrane fusion and payload release. This intermediary approach allows using non-viral structures to achieve viral-level delivery efficiency without viral safety risks.
2Adaptability or versatility
If artificial viruses are designed to deliver multiple therapeutic molecules, then therapeutic capability is enhanced, but formulation complexity increases
Solution Approach 1:
The patent segments the artificial virus into distinct functional modules: the T4 capsid provides structural integrity and targeting, the lipid coating enables membrane fusion and endosomal escape, and the interior space accommodates multiple therapeutic payloads (DNA, RNA, proteins). This segmentation allows independent optimization of each component and simplifies the formulation process by allowing sequential assembly of payloads rather than simultaneous complex mixing.
Solution Approach 2:
The patent implements a nested structure where therapeutic molecules are packaged inside the capsid, which is then coated with lipid layers. Multiple types of therapeutic agents (plasmid DNA, mRNA, siRNA, proteins) can be nested within the same capsid simultaneously. The lipid coating is nested around the capsid, creating a multi-layered delivery vehicle that protects and delivers multiple payloads without increasing overall formulation complexity.
3Productivity
If T4 bacteriophage structure is used for artificial virus construction, then production efficiency is improved, but intracellular delivery efficiency must be enhanced
Solution Approach 1:
The patent changes key parameters of the T4 capsid to adapt it for human cell delivery. Surface proteins are modified to recognize human cell receptors instead of bacterial surfaces. The capsid's physical and chemical properties are adjusted through lipid coating to facilitate endosomal escape and cytoplasmic release. These parameter changes maintain the production efficiency of the T4 system while enabling efficient intracellular delivery to human cells.
Solution Approach 2:
The patent creates a composite structure combining the protein-based T4 capsid with a lipid-based coating. This composite material integrates the production advantages of bacterial phage systems with the delivery advantages of liposomal structures. The capsid-lipid composite maintains structural integrity for efficient production while adding membrane-fusion capabilities for efficient intracellular delivery, solving both requirements simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The T4-based artificial viruses demonstrate high efficiency in delivering genetic payloads into human cells, achieving near 100% transduction efficiency and performing genome editing, gene recombination, gene expression, and gene silencing, with minimal toxicity and broad applicability for personalized medicine.
Implementation Method 1
The exterior of the capsid was then arrayed with Soc- and/or Hoc-fused protein molecules by adding these proteins to the same reaction mixture
Implementation Method 2
The T4-based artificial viruses demonstrate high efficiency in delivering genetic payloads into human cells, achieving near 100% transduction efficiency
Implementation Method 3
A novel artificial virus platform based on bacteriophage T4 is developed, which includes a T4 capsid, Cas9 protein, RNA, DNA
Implementation Method 4
The exterior of the capsid was then arrayed with Soc- and/or Hoc-fused protein molecules by adding these proteins to the same reaction mixture
Data Source
Figure 1A~1F
Figure 2a~2e
Figure 3~4
AI summary
Described is an "artificial virus" (AV) programmed with biomolecules that can enter human cells and carry out precise human genome modification. The AVs comprise: at least one viral vector, such as bacteriophage T4; at least one therapeutic molecule, such as DNA, RNA, protein and their complex; and a lipid coating. Also described is a method of human genome modification, using such an AV, and a method of program such an AV.